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Editorial
The Complex Process of the Health Technology 
Incorporation in Brazil
Áurea J. Chaves
T he transcatheter aortic valve implantation (TAVI, or TAVR, transcatheter aortic valve replacement), the treatment of choice for patients with severe aortic 
stricture deemed inoperable (class I, level of evidence 
B) and an alternative strategy for surgical valve replace-
ment surgery in high-risk individuals (class IIa, level 
of evidence B), has been employed, to date, in over 
700 patients in Brazil. This procedure was approved by 
the Brazilian Federal Council of Medicine in January 
2012, after its evaluation as a non-experimental prac-
tice. This phase was subsequent to the approval of the 
device used in the procedure by the Brazilian Health 
Surveillance Agency (Agência Nacional de Vigilância 
Sanitária – ANVISA).
In the Brazilian system of health technology incor-
poration, compliance with these first two steps does 
not guarantee reimbursement by the private health 
care system or by the Brazilian Unified Health System 
(Sistema Único de Saúde — SUS). To ensure mandatory 
reimbursement by health plans, the procedure should 
integrate the List of Health Procedures and Events de-
veloped by the Brazilian National Regulatory Agency 
for Private Health Insurance and Plans (Agência Nacio-
nal de Saúde Suplementar – ANS), which is renewed 
every two years. To obtain reimbursement by SUS, an 
approval from the National Committee of Technology 
Incorporation (Comissão Nacional de Incorporação 
de Tecnologias – CONITEC) is required. CONITEC 
must issue a ruling within 180 days of request of the 
incorporation.
In the case of TAVI, in three opportunities the 
ANS did not include the technique in the List of Pro-
cedures. In the last update, which will be enforced 
from 2014, a Permanent Technical Group was cre-
ated, which may deliberate in favor of the inclusion 
of new procedures before the regulatory two years. 
At CONITEC, Brazilian Society of Hemodynamics 
and Interventional Cardiology (Sociedade Brasileira 
de Hemodinâmica e Cardiologia Intervencionista – 
SBHCI) claimed for the inclusion of TAVI in March 
2013, and recently the committee launched a public 
consultation for the incorporation of TAVI with the 
recommendation, in a low degree, to not incorpo-
rate this procedure. However, this recommendation 
can be modified after a public consultation, or can 
be opened to contestation, on the appeal level, to 
Ministry of Health.
Some time ago, ANS added, among the criteria 
for inclusion in the list, the economic evaluation of 
the procedure. Under SUS, despite the constitutional 
principle implying that healthcare is a right of all 
and a duty of the State, the access to healthcare is 
conditioned to the existence of budget resources. In 
order to claim again for the inclusion of TAVI in the 
private healthcare system, Queiroga et al., on behalf 
of SBHCI, conducted a study of cost-effectiveness in 
order to include this intervention in the list of pro-
cedures. These authors developed a predictive model 
to evaluate the cost-effectiveness of the procedure in 
long-term. They demonstrated that the incorporation of 
TAVI by ANS would entail an incremental budgetary 
impact over the next five years that is consistent with 
other previously incorporated technologies. Siqueira and 
Abizaid, from Instituto Dante Pazzanese de São Paulo, 
in São Paulo, SP, Brazil, and Kodali and Leon, from 
Columbia University Medical Center/New York Presbyte-
rian Hospital and Cardiovascular Research Foundation, 
New York, United States, in a correspondent editorial, 
estimated that over 45,000 patients could benefit from 
this intervention in Brazil – a fact that is hampered by 
the lack of reimbursement by the private healthcare 
system and SUS. These authors present evidence of the 
clinical value of TAVI, especially in prohibitive surgical 
risk patients: increased life expectancy and quality of 
life; maintenance of the procedure results after five 
years; and decrease of complications associated with 
the intervention with new generation devices. They 
complemented the analysis by revealing results of cost-
effectiveness studies of countries such as the United 
States, Canada, and England that, along with data 
published on this issue, exhibit costs that are similar 
to other medical treatments already incorporated by 
these institutions.
In another prominent article, Andrade et al., from 
Santa Casa de Marília, Marília, SP, Brazil, reported 
the outcomes of patients with acute myocardial infarc-
tion (AMI) undergoing primary percutaneous coronary 
intervention (PCI), comparing those with and without 
resolution of the ST-segment. These authors identified 
the frequency, patient profile, and clinical consequences 
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of those who developed this phenomenon. In a related 
editorial, Abelin and Quadros, from Instituto de Car-
diologia, Fundação Universitária de Cardiologia, Porto 
Alegre (RS), explained that the analysis of ST-segment 
resolution after reperfusion therapy is a useful, simple, 
and inexpensive tool to assess microvascular reperfusion 
that helps to reclassify the patient risk, especially in 
those with Thrombolysis in Myocardial Infarction (TIMI) 
3 flow after primary PCI. These authors review the 
methods used and their role as a prognostic indicator 
and as a research tool in contemporary times.
Complementing this edition are other important 
articles, addressing the predictors of thrombo aspiration 
failure in primary PCI; influence of location of lesions 
in saphenous vein grafts in clinical outcomes after PCI; 
results of PCI by radial route in patients with stable and 
unstable coronary artery disease; outcomes of diabetic 
patients treated with drug-eluting stents (DES) from the 
Safira Registry; changes in the population profile and 
results of PCI in the Angiocardio Registry; evolution 
of patients with cardiogenic shock due to AMI with 
ST-segment elevation; aortic valvuloplasty in patients 
with clinical condition in extremis; interference of 
reprocessed sheaths in occlusion of the radial artery 
after cardiac catheterization; and usefulness of coronary 
angiography and nuclear magnetic resonance imaging 
in the diagnosis of ischaemic cardiomyopathy.
Enjoy your reading!
Áurea J. Chaves 
Editor
